Frontiers in Oncology, Section “Cancer Epidemiology and Prevention” |
| Genetic Variation in the Extended Major Histocompatibility Complex and Susceptibility to Childhood Acute Lymphoblastic Leukemia: A Review of the Evidence |
| Kevin Y Urayama, Pamela D Thompson, Graham Malcolm Taylor, Elizabeth A Trachtenberg, and Anand P Chokkalingam |
| Concordant Oral-Genital HPV Infection in South Africa Couples: Evidence for Transmission |
| Samantha Lee Vogt, Patti E Gravitt, Neil A Martinson, Jennifer Hoffmann, and Gypsyamber DSouza |
| Coverage of Cervical Cancer Screening in Catalonia for the Period 2008–2011 among Immigrants and Spanish-Born Women |
| Vanesa Rodriguez-Sales, Esther Roura, Raquel Ibañez, Mercè Peris, F. Xavier Bosch, and Silvia De Sanjose |
| Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays |
| Hilary Ann Robbins, Troy J Kemp, Carolina Porras, Ana Cecilia Rodriguez, Mark Schiffman, Sholom Wacholder, Paula Gonzalez, John Schiller, Douglas Lowy, Sylviane Poncelet, Mark Esser, Katie Matys, Allan Hildesheim, Ligia A Pinto, Rolando Herrero, and Mahboobeh Safaeian |
Frontiers in Oncology, Section “Cancer Genetics” |
| Skin Tumors Rb(eing) Uncovered |
| CLOTILDE COSTA, Jesus M Paramio, and MIRENTXU SANTOS |
| Melanoma Genetics/Genomics |
| Mike Eccles |
| Genetically Modified T Cells to Target Glioblastoma |
| Simone Krebs, Tania G Rodríguez-Cruz, Christopher DeRenzo, and Stephen Gottschalk |
| What Factors Impact upon a Woman’s Decision to Undertake Genetic Cancer Testing? |
| Julie Anne Quinlivan, Zain Battikhi, and Rodney Waldemar Petersen |
| Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival |
| Stacey Ann N D'mello, Jack U Flanagan, Taryn N Green, Euphemia Y Leung, Marjan E Askarian-Amiri, Wayne R Joseph, Michael R McCrystal, Richard J Isaacs, James H F Shaw, Christopher E Furneaux, Matthew J During, Graeme J FInlay, Bruce C Baguley, and Maggie Lucy Kalev-Zylinska |
Frontiers in Oncology, Section “Cancer Molecular Targets and Therapeutics” |
| The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe |
| Richard J. Epstein |
| Biological Effects of Green Tea Capsule Supplementation in Pre-Surgery Postmenopausal Breast Cancer Patients |
| Steven S Yu, Darcy V Spicer, Debra Hawes, Chiu-Chen Tseng, Chung S Yang, Malcolm C Pike, and Anna H Wu |
| Structural Implications for Selective Targeting of PARPs |
| Jamin D. Steffen, Jonathan R. Brody, Roger S. Armen, and John Matteson Pascal |
|
|
Frontiers in Oncology, Section “Molecular and Cellular Oncology” (Continued) |
| Next-Generation Sequencing of Disseminated Tumor Cells |
| Elen Kristine Møller, Parveen Kumar, Thierry Voet, April Peterson, Peter Van Loo, Randi R. Mathiesen, Renathe Fjelldal, Jason Grundstad, Elin Borgen, Lars O. Baumbusch, Bjørn Naume, Anne-Lise Børresen-Dale, Kevin P. White, Silje Nord, and Vessela N. Kristensen |
| Serglycin: At the Crossroad of Inflammation and Malignancy |
| Angeliki Korpetinou, Spyros S Skandalis, Vassiliki T Labropoulou, Gianna Smirlaki, Argyrios Noulas, Nikos K. Karamanos, and ACHILLEAS D. THEOCHARIS |
| Post-Synthetic Regulation of HS Structure: The Yin and Yang of the Sulfs in Cancer |
| Romain R Vives, Amal Seffouh, and Hugues Lortat-Jacob |
| Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation |
| Turid Hellevik and Inigo Martinez-Zubiaurre |
Frontiers in Oncology, Section “Pharmacology of Anti-Cancer Drugs” |
| Drug-Diagnostics Co-Development in Oncology |
| Richard Simon |
| Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development |
| Jan Stenvang, Iben Kümler, Sune Boris Nygård, David Hersey Smith, Dorte Nielsen, Nils Brünner, and Jose Manuel Afonso Moreira |
| Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling |
| Annika Bettina Foehrenbacher, Timothy W. Secomb, William R. Wilson, and Kevin O Hicks |
| Where is it and How Does it Get There – Intracellular Localization and Traffic of P-glycoprotein |
| Dong Fu |
| Small and Innovative Molecules as New Strategy to Revert MDR |
| Laura Zinzi, Elena Capparelli, Mariangela Cantore, Marialessandra Contino, Marcello Leopoldo, and Nicola Antonio Colabufo |
Frontiers in Oncology, Section “Radiation Oncology” |
| Incident Learning and Failure-Mode-and-Effects-Analysis Guided Safety Initiatives in Radiation Medicine |
| Ajay Kapur, Petrina Zuvic, Gina Goode, Catherine Riehl, Sherin Joseph, Nilda Adair, Michael Interrante, Beatrice Bloom, Lucille Lee, Rajiv Sharma, Anurag Sharma, Jeffrey Antone, Adam Christopher Riegel, Lili Vijeh, Honglai Zhang, Yijian Cao, Carol Morgenstern, Elaine Montchal, Brett Cox, and Louis Potters |
| Quality Assurance for Clinical Trials |
| Geoffrey Stephen Ibbott, Annette Haworth, and David Scott Followill |
| Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients |
| Daniel Grant Petereit |
| Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib |
| Nitesh Rana, Andrew Wenhua Ju, Michael Bazylewicz, Bhaskar Kallakury, Aiwu Ruth He, Keith R Unger, and Justin S Lee |
| Internal Qualification and Credentialing of Radiation Oncology Physicists to Perform Patient Special Procedures |
| Michael D Mills |
| The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond |
| Jorgen Elgqvist, Sofia Frost, Jean-Pierre Pouget, and Per Albertsson |
Frontiers in Oncology, Section “Thoracic Oncology” |
| Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas – Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c |
| Bei Huang, Djeda Belharazem, Li Li, Susanne Kneitz, Philipp Schnabel, Ralf Rieker, Daniel Körner, Winnfried Nix, Berthold Schalke, Hans Konrad Müller-Hermelink, German Ott, Andreas Rosenwald, Philipp Ströbel, and Alexander Marx |
| Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive |
| Ritsuko Komaki and Daniel Gomez |
| Surgical Approaches for Stage IVA Thymic Epithelial Tumors |
| Mark Shapiro and Robert J Korst |
|
